NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Diagnostics & Research · USD

Natera, Inc. (NTRA) Stock Analysis

Natera, Inc. (NTRA) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

NTRA

$328.18

+$0.51 (+0.16%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NTRA with… →

NTRA Key Statistics

As of Sep 4, 2026
Trading
Open
$323.92
Previous Close
$327.67
Day's Range
323.42–329.05
52-Week Range
157.43–343.18
Volume
968.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.53
Valuation
Market Cap
$47.31B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
17.47
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.35
Financials (FY)
Revenue (FY)
$2.31B+35.90%
Net Income (FY)
−$208.16M
Profit marginThe share of revenue left as profit after all costs and taxes.
−7.11%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
144.14M
1-Year Return
+97.03%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
1.39M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

NTRA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+43.25%
2025+44.72%
2024+152.71%
2023+55.94%
2022−56.99%
2021−6.16%
2020+195.40%
2019+141.33%
2018+55.28%
2017−23.23%
2016 (partial year)+2.36%

As of September 4, 2026.

NTRA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.31B−$208.16M−9.0%
2024$1.70B−$190.43M−11.2%
2023$1.08B−$434.80M−40.2%
2022$820.22M−$547.80M−66.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.31B$1.49B−$309.91M−$208.16M−9.0%
2024$1.70B$1.02B−$222.29M−$190.43M−11.2%
2023$1.08B$492.74M−$446.25M−$434.80M−40.2%
2022$820.22M$363.97M−$541.04M−$547.80M−66.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NTRA Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricNTRADiagnostics & Research medianvs median
P/S ratio17.474.993.5x the median
Profit margin−7.11%0.00%7.1 pts below

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Natera, Inc. (NTRA) is capitalised at $47.31B on the latest close. It is classified in the Diagnostics & Research industry, within the Healthcare sector. Headcount on file is 6,135.

NTRA last closed at $328.18 on September 4, 2026. That is +$0.51 (+0.16%) against the previous close. Over the past 52 weeks the price has ranged from $157.43 to $343.18. The latest close sits 108.47% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $2.31B. That is +35.90% against the prior fiscal year, when revenue was $1.70B. The same year closed with a net loss of $208.16M. The reported profit margin is −7.11%. That is 7.1 percentage points below the Diagnostics & Research median of 0%. Trailing earnings per share are −1.35.

Across the 4 fiscal years on file, revenue moves from $820.22M in 2022 to $2.31B in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 17.47. On price-to-sales that is 3.5 times the Diagnostics & Research median of 4.99. 49 Diagnostics & Research companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.53. Annualized volatility over the trailing 10 years is 61.04%. The trailing one-year price return is +97.03%. Across 10 years the annualized return works out at +41.48%.

Growth & Income

The record shows no dividend for NTRA.

The strongest complete calendar year on file is 2020 at +195.40%; the weakest is 2022 at −56.99%. Of the 9 complete calendar years on file, 6 finished higher. 2026 is still running; the price is +43.25% year to date.

Peer Comparison

Natera, Inc. (NTRA) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Natera, Inc. NTRA $47.31B —
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
IQVIA Holdings Inc. IQV $44.07B 33.8

The Diagnostics & Research industry average P/E ratio is 33.1x. Natera, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B

 WAT

Waters Corporation

$40.20B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Natera, Inc.

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

Visit website →